SecBot SecBot
SECBOTREPLAY Home › Report › TOVX

TOVX · Theriva Biologics held its 2026 Annual Meeting on August 3, 2026, where…

Theriva Biologics, Inc. · 8-K filed Aug 4, 2026 at 07:20 ET

At the news

BEARISHIMPACT 4/10

8-K filed Aug 4, 2026 at 07:20 ET

Theriva Biologics held its 2026 Annual Meeting on August 3, 2026, where stockholders approved all six proposals, including an amendment to increase the 2020 Stock Incentive Plan share pool from 4,500,000 to 6,500,000 shares, an increase in authorized common shares, and the issuance of common stock upon warrant exercise. The filing is a routine post-meeting report with no financial results or material corporate events, the increased share authorization and warrant issuance approval signal potential future dilution, but no immediate action has been taken. For a $10M market cap micro-cap, the approval of a 44% increase in the equity incentive pool and a broad authorized share increase is a modestly bearish signal for existing holders, as it enables future dilution without any current operational catalyst to offset it.

  • Stockholders approved Amendment No. 4 to the 2020 Stock Incentive Plan, increasing the share pool from 4,500,000 to 6,500,000 shares (a 44% increase).
  • Stockholders approved an amendment to increase the number of authorized shares of common stock (Charter Amendment), though the Board retains discretion not to file it.
  • Stockholders approved the issuance of common stock upon exercise of outstanding warrants.
  • All four director nominees (Jeffrey J. Kraws, Steven A. Shallcross, John Monahan, Jeffrey Wolf) were re-elected.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access